Medication info
Zocona Tablet 40 mg (Simvastatin)

Zocona Tablet 40 mg (Simvastatin)

Prescription medicationTabletOral
Ingredient · strength
Simvastatin›40mg / 1 tablet
Manufacturer / importer
NexPharm Korea Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200404196 · Notified 2004.09.21 · Insurance code 662501500

Summary

Main use
Improvement of hyperlipidemia and pediatric familial hypercholesterolemia; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine. 1. Reduction of cardiovascular risk Adult patients at high risk of coronary heart disease events due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended initial dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. The recommended dose is 5 ~ 40 mg of this medicine once daily in the evening. Adjust the dose appropriately according to the initial LDL cholesterol level before starting treatment, the treatment goal, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if the cholesterol level falls below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of this medicine at a dose of 80 mg is restricted to patients who have taken 80 mg of this medicine for 12 months or longer without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) For the recommended doses in patients taking this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in certain patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), refer to the information below (see 6. Drug Interactions under Precautions for Use). (1) Administration to patients with homozygous familial hypercholesterolemia In controlled clinical trials, patients with homozygous familial hypercholesterolemia received 40 mg of this medicine once daily in the evening. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when other lipid-lowering treatments are not available. (2) In elderly patients, the maximum reduction in cholesterol levels may be achieved with a daily dose of 20 mg of this medicine. (3) Administration to patients taking verapamil, diltiazem, or dronedarone When this medicine is administered concomitantly to patients taking verapamil, diltiazem, or dronedarone, the dose of this medicine should not exceed 10 mg per day. (4) Administration to patients taking amiodarone, amlodipine, or ranolazine When this medicine is administered concomitantly to patients taking amiodarone, amlodipine, or ranolazine, the dose of this medicine should not exceed 20 mg per day. (5) Concomitant administration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is administered concomitantly with a fibrate (excluding gemfibrozil (see 2. Do not administer to the following patients under Precautions for Use) and fenofibrate), the dose of this medicine should not exceed 10 mg per day. (6) Administration to patients with renal impairment Since this medicine is not substantially excreted by the kidneys, dose adjustment is not required in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, the initial dose should be 5 mg per day, and the patient should be monitored carefully.
Child dose
3. Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this drug once daily, administered in the evening. The recommended dosage range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. The dose should be adjusted as appropriate for each patient according to the recommended treatment goals. Dose adjustments should be made at intervals of 4 weeks or longer.

Ingredients

Manufacturer
NexPharm Korea Co., Ltd.

Efficacy & effects

Improvement of hyperlipidemia and pediatric familial hypercholesterolemia; prevention of cardiovascular disease

  • Coronary heart disease
  • diabetes
  • peripheral vascular disease
  • stroke
  • other cerebrovascular diseases
  • hypercholesterolemia
  • dyslipidemia
  • abnormal beta-lipoproteinemia
  • hypertriglyceridemia
  • familial heterozygous hypercholesterolemia
View approved original text

This medication helps reduce the risk of cardiovascular diseases such as coronary heart disease and stroke. Additionally, it lowers cholesterol and triglyceride levels in patients with hyperlipidemia and increases the levels of high-density lipoprotein (HDL) cholesterol to help maintain healthy blood vessels. It can be used in combination with dietary measures for pediatric patients over 10 years old who have familial hypercholesterolemia. By effectively managing risk factors for cardiovascular diseases, it reduces the occurrence of serious complications such as heart attacks and strokes. Lipid levels must be closely monitored before starting treatment to ensure safe therapy. This medication is used to improve cardiovascular health and assist in cholesterol management.

How to take

Adult dose

Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine. 1. Reduction of cardiovascular risk Adult patients at high risk of coronary heart disease events due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended initial dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. The recommended dose is 5 ~ 40 mg of this medicine once daily in the evening. Adjust the dose appropriately according to the initial LDL cholesterol level before starting treatment, the treatment goal, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if the cholesterol level falls below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of this medicine at a dose of 80 mg is restricted to patients who have taken 80 mg of this medicine for 12 months or longer without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) For the recommended doses in patients taking this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in certain patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), refer to the information below (see 6. Drug Interactions under Precautions for Use). (1) Administration to patients with homozygous familial hypercholesterolemia In controlled clinical trials, patients with homozygous familial hypercholesterolemia received 40 mg of this medicine once daily in the evening. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when other lipid-lowering treatments are not available. (2) In elderly patients, the maximum reduction in cholesterol levels may be achieved with a daily dose of 20 mg of this medicine. (3) Administration to patients taking verapamil, diltiazem, or dronedarone When this medicine is administered concomitantly to patients taking verapamil, diltiazem, or dronedarone, the dose of this medicine should not exceed 10 mg per day. (4) Administration to patients taking amiodarone, amlodipine, or ranolazine When this medicine is administered concomitantly to patients taking amiodarone, amlodipine, or ranolazine, the dose of this medicine should not exceed 20 mg per day. (5) Concomitant administration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is administered concomitantly with a fibrate (excluding gemfibrozil (see 2. Do not administer to the following patients under Precautions for Use) and fenofibrate), the dose of this medicine should not exceed 10 mg per day. (6) Administration to patients with renal impairment Since this medicine is not substantially excreted by the kidneys, dose adjustment is not required in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, the initial dose should be 5 mg per day, and the patient should be monitored carefully.

Child dose

3. Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this drug once daily, administered in the evening. The recommended dosage range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. The dose should be adjusted as appropriate for each patient according to the recommended treatment goals. Dose adjustments should be made at intervals of 4 weeks or longer.

Precautions

This medication can cause serious muscle-related side effects such as myopathy and rhabdomyolysis; therefore, caution is required, especially for patients taking high doses. Patients with impaired liver function or active liver disease, pregnant or nursing women should not take this medication. If symptoms such as liver dysfunction, muscle pain, or muscle weakness occur, inform a doctor immediately, and discontinue the medication if necessary. This medication can interact with various drugs, so inform your physician or pharmacist if you are taking other medications. Avoid concurrent use with strong CYP3A4 inhibitors, gemfibrozil, cyclosporine, danazol, etc., as this increases the risk of myopathy. Elderly patients, those with decreased kidney function, and patients with hypothyroidism should use this medication with caution. Women who are pregnant or may become pregnant must use contraception, and should stop taking the medication if pregnancy is confirmed. This medication contains lactose; patients with lactose intolerance should not take it. During treatment, regular checks of liver function and muscle-related tests are recommended, and consult healthcare providers immediately if any abnormal symptoms occur. Special attention is needed when administering to children and adolescents, and it is not recommended for children under 10 years old. Store this medication out of the reach of children and keep it in its original container.

Side effects

  • myopathy
  • rhabdomyolysis
  • abdominal pain
  • weakness
  • constipation
  • diarrhea
  • indigestion
  • bloating
  • nausea
  • headache
Show 91 more
  • upper respiratory infection
  • edema
  • atrial fibrillation
  • gastritis
  • diabetes
  • myalgia
  • insomnia
  • dizziness
  • bronchitis
  • sinusitis
  • eczema
  • urinary tract infection
  • immune-mediated necrotizing myopathy
  • taste disturbance
  • ocular movement disorder
  • facial weakness
  • tremor
  • sensory disturbance
  • peripheral neuropathy
  • peripheral nerve palsy
  • psychiatric disorder
  • anxiety
  • sleep disturbance
  • nightmares
  • depression
  • cognitive impairment
  • myasthenia gravis
  • ocular myasthenia
  • hepatitis
  • liver dysfunction
  • jaundice
  • pancreatitis
  • liver failure
  • cholestatic jaundice
  • hepatic steatosis
  • cirrhosis
  • fulminant hepatic necrosis
  • hepatocellular carcinoma
  • loss of appetite
  • vomiting
  • alopecia
  • pruritus
  • skin changes
  • lichenoid drug eruption
  • gynecomastia
  • decreased libido
  • sexual dysfunction
  • progression of cataract
  • ophthalmoplegia
  • anemia
  • elevated aminotransferases
  • elevated alkaline phosphatase
  • elevated gamma-GTP
  • elevated bilirubin
  • abnormal thyroid function
  • elevated serum creatine kinase
  • interstitial lung disease
  • anaphylaxis
  • angioedema
  • lupus-like syndrome
  • polymyositis
  • dermatomyositis
  • vasculitis
  • purpura
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • positive antinuclear antibodies
  • increased erythrocyte sedimentation rate
  • eosinophilia
  • arthritis
  • arthralgia
  • urticaria
  • photosensitivity
  • fever
  • chills
  • flushing
  • malaise
  • dyspnea
  • toxic epidermal necrolysis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • limb sensory numbness
  • paresthesia
  • cold sensation
  • muscle weakness
  • thrombocytopenia
  • interstitial lung disease
  • fever
  • weight loss
  • fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air and moisture from entering. It is essential to maintain a storage temperature between 1°C and 30°C to ensure the safety and efficacy of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.